Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accumulated Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Accumulated Expenses for 6 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 39.44% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 39.44% decrease, with the full-year FY2025 number at $4.1 million, down 39.44% from a year prior.
  • Accumulated Expenses was $4.1 million for Q4 2025 at TScan Therapeutics, roughly flat from $4.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $7.1 million in Q2 2025 to a low of $1.1 million in Q2 2021.
  • A 5-year average of $4.0 million and a median of $4.1 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 66.09% in 2022, then skyrocketed 314.37% in 2023.
  • TScan Therapeutics' Accumulated Expenses stood at $2.6 million in 2021, then plummeted by 49.15% to $1.3 million in 2022, then surged by 314.37% to $5.5 million in 2023, then rose by 24.95% to $6.8 million in 2024, then tumbled by 39.44% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Accumulated Expenses are $4.1 million (Q4 2025), $4.2 million (Q3 2025), and $7.1 million (Q2 2025).